Antifibrinolytic Therapy in Cardiac Surgery

  • J. J. Lehot
  • P. Ffrench
  • J. F. Obadia
Conference paper


Both clot lysis and platelet dysfunction contribute to bleeding after cardiopulmonary bypass (CPB). Aprotinin (APT), an antifibrinolytic agent derived from bovine lung, and tranexamic acid (TA) and epsilon-aminocaproic acid (EACA), two synthetic lysine-analog antifibrinolytics, are administered prophylactically before or during CPB to reduce excessive bleeding and transfusion of homologous blood products after cardiac surgery. The majority of studies confirms their efficacy but the possibility of adverse effects and their cost must be taken into account to rationalize their utilization.


Cardiopulmonary Bypass Tranexamic Acid Postoperative Blood Loss Blood Product Transfusion Antifibrinolytic Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Editorial (1988) Can drugs reduce surgical blood loss? Lancet 1:155–156Google Scholar
  2. 2.
    Marx G, Pokar H, Reuter H et al (1991) The effects of aprotinin on hemostatic function during cardiac surgery. J Thorac Cardiovasc Anesth 5:467–474Google Scholar
  3. 3.
    Huyzen RJ, Harder MP, Gallandat Huet RCG et al (1994) Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin treated patients. J Cardiothorac Vase Anesth 8:153–156CrossRefGoogle Scholar
  4. 4.
    Tabuchi N, Njo TL, Tigchelaar I et al (1994) Monitoring of anticoagulation in aprotinin treated patients during heart operation. Ann Thorac Surg 58:774–777PubMedCrossRefGoogle Scholar
  5. 5.
    Hunt BJ, Segal HC, Yacoub M (1992) Guidelines for monitoring heparin by the activated clotting time when aprotinin is used during cardiopulmonary bypass. J Thorac Cardiovasc Surg 104:211–212PubMedGoogle Scholar
  6. 6.
    Bailey CR, Fischer AR, Wielogorski AK (1994) Reheparinisation requirements after cardiopulmonary bypass in patients treated with aprotinin. Br Heart J 72:442–445PubMedCrossRefGoogle Scholar
  7. 7.
    Royston D, Taylor KM, Bidstrup BP et al (1987) Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 11:1289–1291CrossRefGoogle Scholar
  8. 8.
    Van Oeveren W, Jansen NJG, Bidstrup BP et al (1987) Effects of aprotinin on hemostatic mechanism during cardiopulmonary bypass. Ann Thorac Surg 44:640–645PubMedCrossRefGoogle Scholar
  9. 9.
    Alajmo F, Calamai G, Perna AM et al (1989) High-dose aprotinin: hemostatic effects in open heart operations. Ann Thorac Surg 48:536–539PubMedCrossRefGoogle Scholar
  10. 10.
    Bidstrup BP, Royston D, Taylor KM (1989) Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 97: 364–372PubMedGoogle Scholar
  11. 11.
    Fraedrich G, Weber C, Bernard C et al (1989) Reduction of blood transfusion requirement in open heart surgery by administration of high doses of aprotinin-preliminary results. Thorac Cardiovasc Surgeon 37:89–91CrossRefGoogle Scholar
  12. 12.
    Dietrich W, Spannagi M, Jochum M et al (1990) Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 73:1119–1126PubMedCrossRefGoogle Scholar
  13. 13.
    Van Oeveren W, Harder MP, Roozendaal KJ et al (1990) Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 99:788–797PubMedGoogle Scholar
  14. 14.
    Harder MP, Eijsman L, Roozendaal KJ et al (1991) Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Ann Thorac Surg 51:936–941PubMedCrossRefGoogle Scholar
  15. 15.
    Baele PL, Ruiz-Gomez J, Londot C et al (1992) Systematic use of aprotinin in cardiac surgery: influence on total homologous exposure and hospital cost. Acat Anaesth Belg 43: 103–112Google Scholar
  16. 16.
    Cosgrove III DM, Heric B, Lytle BW et al (1992) Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 54:1031–1038PubMedCrossRefGoogle Scholar
  17. 17.
    Vedrinne C, Girard C, Jegaden O et al (1992) Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vase Anesth 6:319–323CrossRefGoogle Scholar
  18. 18.
    Sundt TM, Kouchoukos NT, Saffits JE et al (1993) Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 55:1418–1424PubMedCrossRefGoogle Scholar
  19. 19.
    Blauhut B, Harringer W, Bettelheim P et al (1994) Comparison of the effects of aprotinin and tranexamic acid on blood loss and related variables after cardiopulmonary bypass. J Thorac Cardiovasc Surg 108:1083–1091PubMedGoogle Scholar
  20. 20.
    Laub GW, Riebman JB, Chen C et al (1994) The impact of aprotinin on coronary artery bypass graft patency. Chest 106:1370–1375PubMedCrossRefGoogle Scholar
  21. 21.
    Murkin JM, Lux J, Shannon NA et al (1994) Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 107:554–556PubMedGoogle Scholar
  22. 22.
    Bailey CR, Kelleher AA, Wielogorski AK (1994) Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg 81:969–973PubMedCrossRefGoogle Scholar
  23. 23.
    Goldstein DJ, DeRosa CM, Mongero LB et al (1995) Safety and efficacy of aprotinin under conditions of deep hypothermia and circulatory arrest. J Thorac Cardiovasc Surg 110:1615–1622PubMedCrossRefGoogle Scholar
  24. 23.
    Goldstein DJ, Seldomridge A, Chen JM et al (1995) Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg 59:1063–1068PubMedCrossRefGoogle Scholar
  25. 25.
    Levy JH, Pifarre R, Schaff HV et al (1995) A multicenter, double blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 92:2236–2244PubMedCrossRefGoogle Scholar
  26. 26.
    Hendrice C, Schmartz D, Pradier O et al (1995) Effects of aprotinin on blood loss, heparin doses in patients undergoing coronary artery bypass surgery. J Cardiothorac Vase Anesth 9: 245–249CrossRefGoogle Scholar
  27. 27.
    Corbeau JJ, Monrigal JP, Jacob JP et al (1995) Comparaison des effets de l’aprotinine et de l’acide traneamique sur le saignement en chirurgie cardiaque. Ann Fr Anesth Réanim 14: 154–161PubMedCrossRefGoogle Scholar
  28. 28.
    Locatelli A, Maurelli M, Bianchi T et al (1991) Aprotinin in cardiac sugery. Lancet 338:254PubMedCrossRefGoogle Scholar
  29. 29.
    Van der Meer J, Hillege HL, Ascoop CAP et al (1996) Aprotinin in aortocoronary bypass surgery: increased risk of vein-graft occlusion and myocardial infarction? Supportive evidence from a retrospective study. Thrombosis Hemostasis 75:1–3Google Scholar
  30. 30.
    Carrel T, Bauer E, Laske A et al (1991) Low-dose aprotinin also allows reduction of blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg 102:801 (letter)PubMedGoogle Scholar
  31. 31.
    Madi-Jebara S, Benmosbah L, Massonnet-Castel S et al (1992) Blood saving effects after cardiac surgery: low dose aprotinin versus tranexamic acid. Anethesiology 77:A312CrossRefGoogle Scholar
  32. 32.
    Kawasuji M, Ueyama K, Sakakibara N et al (1993) Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg 55:1205–1209PubMedCrossRefGoogle Scholar
  33. 33.
    Schönberger JPAM, Bredée JJ, Van Oeveren W et al (1993) Preoperative therapy of low-dose aspirin in internal mammary artery bypass operations with and without low-dose aprotinin. J Thorac Cardiovasc Surg 106:262–267PubMedGoogle Scholar
  34. 34.
    Rocha E, Hidalgo F, Llorens R et al (1994) Randomized study of aprotinin and DDAVP to reduce postoperative bleeding after cardiopulmonary bypass surgery. Circulation 90:921–927PubMedCrossRefGoogle Scholar
  35. 35.
    Tabuchi N, Huet RCG, Sturk A et al (1994) Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg 58:1036–1039PubMedCrossRefGoogle Scholar
  36. 36.
    Bailey CR, Wielogorski AK (1994) Randomized placebo controlled double blind study of two low dose aprotinin regimen in cardiac surgery. Br Heart J 71:349–353PubMedCrossRefGoogle Scholar
  37. 37.
    Alvarez JM, Quiney NF, McMillan D et al (1995) The use of ultra-low-dose aprotinin to reduce blood loss in cardiac surgery. J Cardiothorac Vase Anesth 9:29–33CrossRefGoogle Scholar
  38. 38.
    Pugh SC, Wielogorski AK (1995) A comparison of the effects of tranexamic acid and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing cardiac surgery. J Cardiothorac Vase Anesth 9:240–244CrossRefGoogle Scholar
  39. 39.
    Speekenbrink RGH, Vonk ABA, Wildevuur CRH et al (1995) Hemostatic efficacy of dipyridamole, tranexamic acid, and aprotinin in coronary bypass grafting. Ann Thorac Surg 59:438–442PubMedCrossRefGoogle Scholar
  40. 40.
    Boldt J, Knothe C, Zickmann B et al (1993) Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 105:705–711PubMedGoogle Scholar
  41. 41.
    Boldt J, Zickman B, Schindler E et al (1994) Influence of aprotinin on the thrombomodulin protein C system in pediatric cardiac operations. J Thorac Cardiovasc Surg 107:1215–1221PubMedGoogle Scholar
  42. 42.
    Herynkopf F, Lucchese F, Pereira D et al (1994) Aprotinin in children undergoing correction of congenital heart defects. J Thorac Cardiovasc Surg 108:517–521PubMedGoogle Scholar
  43. 43.
    Penkoske PA, Entwistle LM, Marchak EB et al (1995) Aprotinin in children undergoing repair of congenital heart defects. Ann Thorac Surg 60:S529–532PubMedCrossRefGoogle Scholar
  44. 44.
    Zonis Z, Seear M, Reichert C et al (1996) The effect of preoperative tranexamic acid on blood loss after cardiac operations in children. J Thorac Cardiovasc Surg 111:982–987PubMedCrossRefGoogle Scholar
  45. 45.
    Jegaden O, Vedrinne C, Rossi R (1993) Aprotinin does not compromise arterial graft patency in coronary bypass operations. Letters to the Editor. J Thorac Cardiovasc Surg 106:180–186PubMedGoogle Scholar
  46. 46.
    Bukhari EA, Krukenkamp IB, Burns PG et al (1995) Does aprotinin increase the myocardial damage in the setting of ischemia and preconditioning? Ann Thorac Surg 60:307–310PubMedCrossRefGoogle Scholar
  47. 47.
    Bohrer H, Fleischer F, Lang J et al (1990) Early formation of thrombi on pulmonary artery catheters in cardiac surgical patients receiving high-dose aprotinin. J Cardiothorac Anesth 4:222–225PubMedCrossRefGoogle Scholar
  48. 48.
    Lemmer JH, Stanford W, Bonney SL et al (1995) Aprotinin for coronary artery bypass grafting: effect on postoperative renal function. Ann Thorac Surg 59:132–136PubMedCrossRefGoogle Scholar
  49. 49.
    LaFerla AG, Murray WR (1984) Anaphylactic reaction to aprotinin despite negative ocular sensitivity tests. Br Med J 289:1176–1177CrossRefGoogle Scholar
  50. 50.
    Isetta C, Garraffo R, Merville C et al (1996) Pharmacokinetic study of tranexamic acid during cardiac surgery with cardiopulmonary bypass. Anesth Analg 82:S199Google Scholar
  51. 51.
    Yau TM, Carson S, Weisel RD et al (1992) The effect of warm heart surgery on postoperative bleeding. J Thorac Cardiovasc Surg 103:1155–1163PubMedGoogle Scholar
  52. 52.
    Karski JM, Teasdale S J, Norman PH et al (1993) Prevention of postbypass bleeding with tranexamic acid and aminocaproic acid. J Cardiothorac Vase Anesth 7:431–435CrossRefGoogle Scholar
  53. 53.
    Couto WJ, Gregori JF, Cordeiro CO et al (1994) Use of tranexamic acid for bleeding control in myocardial revascularization. Arq Bras Cardiol 63:485–487PubMedGoogle Scholar
  54. 54.
    Horrow JC, Van Riper DF, Strong MD et al (1995) The dose-response relationship of tranexamic acid. Anesthesiology 82:383–392PubMedCrossRefGoogle Scholar
  55. 55.
    Karski JM, Teasdale S J, Norman P et al (1995) Prevention of bleeding after cardiopulmonary bypass with high dose tranexamic acid. Double blind, randomized clinical trial. J Thorac Cardiovasc Surg 110:835–842PubMedCrossRefGoogle Scholar
  56. 56.
    Rousou JA, Engelman RM, Flack JE et al (1995) Tranexamic acid significantly reduces blood loss associated with coronary revascularization. Ann Thorac Surg 59:671–675PubMedCrossRefGoogle Scholar
  57. 57.
    Katsaros D, Petricevic M, Snow NJ et al (1996) Tranexamic acid reduces postbypass blood use: a double blinded, prospective, randomized study of 210 patients. Ann Thorac Surg 61: 1131–1135PubMedCrossRefGoogle Scholar
  58. 58.
    Horrow JC, Hlavacek J, Strong MD et al (1990) Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 99:70–74PubMedGoogle Scholar
  59. 59.
    Horrow JC, Van Riper DF, Strong MD et al (1991) Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 84:2063–2070PubMedCrossRefGoogle Scholar
  60. 60.
    Isetta C, Samat C, Kotaiche et al (1991) Réduction des besoins transfusionnels homologues en chirurgie cardiaque sous aprotinine et sous acide tranéxamique. Ann Fr Anesth Réanim 10 [Suppl]:R122Google Scholar
  61. 61.
    Nakashima A, Matsuzaki K, Fukumura F et al (1993) Tranexamic acid reduces blood loss after cardiopulmonary bypass. ASAIO J 39:M185–189PubMedCrossRefGoogle Scholar
  62. 62.
    Ovrum E, Am Holen E, Abdelnoor M et al (1993) Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations. J Thorac Cardiovasc Surg 105:78–83PubMedGoogle Scholar
  63. 63.
    Coffey A, Pittmam J, Halbrook H et al (1995) The use of tranexamic acid to reduce postoperative bleeding following cardiac surgery: a double-blind randomized trial. Am Surg 61:566–568PubMedGoogle Scholar
  64. 64.
    Shore-Lesserson L, Reich DL, Vela-Cantos F et al (1996) Tranexamic acid inhibits fibrinolysis and bleeding in repeat cardiac surgery. Anesth Analg 82:S408Google Scholar
  65. 65.
    Shore-Lesserson L, Reich DL, Vela-Cantos F et al (1996) Tranexamic acid reduces transfusions in repeat cardiac surgery. Anesth Analg 82:S409Google Scholar
  66. 66.
    Magnani BJ, Morse D, Fox J et al (1996) Effects of epsilon-aminocaproic acid on platelet markers. Abstract D 103, 11th World Congress of Anaesthesiologists, SydneyGoogle Scholar
  67. 67.
    Delrossi AJ, Cernaianu AC, Botros S et al (1989) Prophylactic treatment of postperfusion bleeding using EACA. Chest 96:27–30PubMedCrossRefGoogle Scholar
  68. 68.
    Trinh-Duc P, Wintrebert P, Boulfroy D et al (1992) Comparaison des effets de l’acide e-aminocaproïque et de P aprotinine sur le saignement per- et post-opératoire en chirurgie cardiaque. Ann Chir Thorac Cardiovasc 46:677–683Google Scholar
  69. 69.
    Arom KV, Emery RW (1994) Decreased postoperative drainage with addition of e-amino-caproic acid before cardiopulmonary bypass. Ann Thorac Surg 57:1108–1113PubMedCrossRefGoogle Scholar
  70. 70.
    Jordan D, Delphin E, Rose E (1995) Prophylactic e-aminocaproic acid (EACA) administration minimized blood replacement therapy during cardiac surgery. Anesth Analg 80:827–829PubMedGoogle Scholar
  71. 71.
    Magovern JA, Sakert T, Benckart DH et al (1996) A model for predicting transfusion after coronary artery bypass grafting. Ann Thorac Surg 61:27–32PubMedCrossRefGoogle Scholar
  72. 72.
    Despotis GJ, Filos KS, Zoys TN et al (1996) Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 82:13–21PubMedGoogle Scholar
  73. 73.
    Bidstrup BP, Harrison J, Royston D et al (1993) Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 55:971–976PubMedCrossRefGoogle Scholar
  74. 74.
    Bidstrup BP, Royston D, Taylor KM et al (1988) Effect of aprotinin on need for blood transfusion in patients with septic endocarditis having open heart surgery. Lancet 1:366–367PubMedCrossRefGoogle Scholar
  75. 75.
    Murkin JM, McKenzie FN, White S et al (1994) A randomized comparison of the efficacy of high or low dose aprotinin, or tranexamic acid, to decrease blood loss and transfusion requirements in aspirin-treated cardiac surgical patients. Can J Anaesth 41:A33Google Scholar
  76. 76.
    Durinck L, Roussel B, Gross S et al (1994) Chirurgie cardiaque et antifibrinolytiques: aprotinine à faible dose ou acide tranéxamique? Ann Fr Anesth Réanim 13:R336CrossRefGoogle Scholar
  77. 77.
    Casati V, Guzzon D, Oppizzi M et al (1996) High dose aprotinin vs tranexamic acid in selective cardiac surgery: effects on bleeding and necessity of transfusion. BJA 76:A53Google Scholar
  78. 78.
    Fremes SE, Wong BI, Lee E et al (1994) Metaanalysis of prophylactic during treatment in the prevention of postoperative bleeding. Ann Thorac Surg 58:1580–1588PubMedCrossRefGoogle Scholar
  79. 79.
    Angelini GD, Cooper GJ, Lamarra M et al (1990) Unorthodox use of aprotinin to control life-threatening bleeding after cardiopulmonary bypass. Lancet 335:799–800PubMedCrossRefGoogle Scholar
  80. 80.
    Reid RW, Babik B, Burrows FA et al (1996) Are synthetic antifibrinolytics associated with an increased incidence of baffle fenestration occlusion following modified fontan procedure? Anesth Analg 82:S375Google Scholar

Copyright information

© Springer-Verlag Italia 1997

Authors and Affiliations

  • J. J. Lehot
  • P. Ffrench
  • J. F. Obadia

There are no affiliations available

Personalised recommendations